MedPath

Aldafermin

Generic Name
Aldafermin
Drug Type
Biotech
CAS Number
1616639-03-2
Unique Ingredient Identifier
IK9NYN31ZM
Background

Aldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)).

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

Phase 2
Withdrawn
Conditions
Primary Sclerosing Cholangitis
Interventions
Drug: Placebo
First Posted Date
2024-10-23
Last Posted Date
2025-05-07
Lead Sponsor
NGM Biopharmaceuticals, Inc
Target Recruit Count
300
Registration Number
NCT06654726
Locations
🇺🇸

NGM Clinical Study Site, Seattle, Washington, United States

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Phase 2
Completed
Conditions
Chronic Diarrhea
Bile Acid Diarrhea
Irritable Bowel Syndrome With Diarrhea
Bile Acid Malabsorption
Functional Diarrhea
Bile Acid Malabsorption Syndrome Type II
Interventions
Drug: Placebo
First Posted Date
2021-11-22
Last Posted Date
2023-10-12
Lead Sponsor
Michael Camilleri, MD
Target Recruit Count
30
Registration Number
NCT05130047
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Phase 2
Completed
Conditions
Compensated Cirrhosis
Nonalcoholic Steatohepatitis
Interventions
First Posted Date
2019-12-24
Last Posted Date
2025-03-26
Lead Sponsor
NGM Biopharmaceuticals, Inc
Target Recruit Count
160
Registration Number
NCT04210245
Locations
🇵🇷

NGM Clinical Study Site, San Juan, Puerto Rico

🇺🇸

NGM Clinical Study Site 413, Tucson, Arizona, United States

🇺🇸

NGM Clinical Study Site 415, Tucson, Arizona, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath